Adial Pharmaceuticals regains Nasdaq minimum bid price compliance; highlights advanced AD04 partnering discussions

ADIAL PHARMACEUTICALS, INC.

Received Nasdaq notice on Feb. 23, 2026 that closing bid price was ≥$1.00 for 10 consecutive business days (Feb. 6-20, 2026).
Nasdaq confirmed compliance with Listing Rule 5550(a)(2) and closed the matter.
CEO Cary Claiborne stated the company is engaged in advanced strategic partnering discussions for AD04.
AD04 is a genetically targeted serotonin-3 receptor antagonist for Alcohol Use Disorder, moving toward Phase 3 program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.